The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724.

The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Abstract Text:

The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Publishing Authors By Initials

For similar neoplasms: neoplasms, experimental research abstracts see: neoplasms: neoplasms, experimental research

PUBMED ID PMID:

MEDLINE DATE:

The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: UCLA [reports]. U.S. Atomic Energy Commission

VOLUME:

Page Numbers: 67-8

Journal Abbreviation:

ISSN:

DAY: 30

MONTH: Jun

YEAR: 1969

The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 21830740

The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Keywords Mesh Terms:

KEYWORDS: Neoplasms, Experimental

MESH TERMS: immunology

Chemical & Substance for Abstract: The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724. Information

Substance Name: Immunosuppressive Agents

Registry Number: 0

Grant and Affiliation Information for The effects of antilymphocytic serum (ALS) on the development of lymphoma in mice. UCLA 12-724.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: UCLA Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The effects of antilymphocytic serum ALS on the development of lymphoma in mice UCLA 12-724 Related Publications

• A mechanism-based cancer risk assessment for 1,4-dichlorobenzene.
• Acute effects of cocaine in two models of inhibitory control: implications of non-linear dose effects.
• Cognitive-behavioural treatment for men with intellectual disabilities and sexually abusive behaviour: a pilot study.
• Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I.
• Developing a Spanish-language consumer report for CAHPS health plan surveys.
• Direct observation of regulated ribonucleoprotein transport across the nurse cell/oocyte boundary.
• Discrimination between wild-type and ampicillin-resistant Escherichia coli by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
• Doppler line profile analysis for a multichannel Fabry-Perot interferometer.
• Drusilla rageu poole 1921-1981.
• Effect of halogenated ethylamines on cardiac arrhythmias induced by epinephrine, nicotine and cyclopropane.
• Human DNA mismatch repair: coupling of mismatch recognition to strand-specific excision.
• Human monoclonal IgM anti-Gal(beta 1-3)GalNAc autoantibodies bind to the surface of bovine spinal motoneurons.
• Localization of GM1 and Gal(beta 1-3)GalNAc antigenic determinants in peripheral nerve.
• Localization of neural epitopes that bind to IgM monoclonal autoantibodies (M-proteins) from two patients with motor neuron disease.
• Lost in translation.
• Manifest refraction.
• Mitochondrial membrane depolarization in Drosophila apoptosis.
• On the cover.
• Parenteral thyroxine administration.
• Pressurized oxygen therapy; final report of a new method.
• Reaching East.
• Reforming medical education in the United Kingdom: lessons for Australia and New Zealand.
• Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.
• Retention of B vitamins after large-scale cooking of meat; suitability of left and right muscles for retention studies.
• Retention of B vitamins in beef and veal after home canning and storage.
• Role of oxidative stress in arsenic-induced toxicity.
• Solving the puzzle of hormone replacement.
• The SF-36 physical and mental health factors were confirmed in cancer and HIV/AIDS patients.
• The role of the bifactor model in resolving dimensionality issues in health outcomes measures.
• What is sufficient evidence for the reliability and validity of patient-reported outcome measures?